INTRODUCTION

A 53-year-old woman was admitted at our hospital for the treatment of acute myeloid leukemia (AML). Heterozygous c.566C>T mutation in the TP53 gene was found in leukemia cells and germline cells. The number of germline mutation found incidentally will increase. Therefore, patients with such incidental findings must undergo adequate genetic counseling.

Li-Fraumeni syndrome is mainly caused by pathogenic germline mutations of the TP53 gene, most commonly missense mutations. Germline TP53 c.566C>T mutation results in the missense mutation at codon (A189V). This mutation has been observed in late-onset cancer such as multiple primary colon tumors, breast cancer, and fallopian tube carcinoma.1-3 Moreover, it was classified as a variant with uncertain significance. Recently, it was found not to be rare.4 However, the association between this mutation and hematological malignancy is unclear. Herein, we report a case of germline TP53 c.566C>T mutation, which was incidentally diagnosed during the treatment of AML.
and platelet count: $5.0 \times 10^9/L$. The patient's C-reactive protein level was elevated at 33.17 mg/μl.

Based on the pathologic examination, the bone marrow aspirate exhibited hypercellularity with 87% of blast cells. Chromosome analysis of leukemia cells revealed a complex karyotype (46, XX, add(4)(q21), add(10)(p11.2) [9]/46, idem, add(14)(q22)[3]/46, XX [3]). Approximately 87% of the leukemia cell population tested positive for CD34, HLA-DR, myeloperoxidase, and CD33. Meanwhile, the blast cell population tested negative for CD13 and CD38.

3 | DIFFERENTIAL DIAGNOSIS, INVESTIGATIONS, AND TREATMENT

Appendectomy and abdominal lavage were performed 2 days after admission. The initial chemotherapy was delayed for 7 days to allow for adequate wound healing postoperatively. The patient received induction chemotherapy for AML (aclarubicin 14 mg/m² for 4 days, cytarabine 20 mg/m² for 14 days, and granulocyte colony-stimulating factor [CAG regimen]). Hematological complete remission was achieved after four cycles of chemotherapy. However, 1% of leukemia cells remained in the bone marrow, which was confirmed via a flow cytometry analysis. Azacitidine (75 mg/m² for 7 days) and venetoclax (50 mg/body weight daily) regimen were provided as a maintenance therapy. According to the National Comprehensive Cancer Network guidelines, this patient had a poor prognosis. Hematopoietic stem cell transplantation was planned. After two courses of azacitidine-venetoclax regimen, the patient received umbilical cord blood transplantation.

Somatic TP53 mutations of the AML cells were examined to predict prognosis. Heterozygous c.566C>T mutation was found in AML cells (Figure 2A). Because germline TP53 mutation was suspected, the hematologist referred the patient to the department of clinical genetics in our hospital. Analysis of the peripheral blood revealed a germline heterozygotic c.566C>T mutation in the AML specimen (Figure 2B). The analysis was performed after the achievement of complete remission and before umbilical cord transplantation. We also checked the mutation in the buccal epithelium.

4 | OUTCOME AND FOLLOW-UP

We recommended that her two daughters (FIV-1, aged 24 years, and FIV-2, aged 20 years) undergo genetic counseling. Any other members of the family were not checked for c.566C>T germline mutation.
5 | DISCUSSION

The current case report aimed to provide oncologists with information about possible incidental findings including germline mutation.

*TP53* is an extremely important tumor suppressor gene. Germline mutation in the *TP53* gene causes Li-Fraumeni syndrome, a rare hereditary cancer syndrome. Somatic deleterious mutation in both alleles of the *TP53* gene is commonly observed in sporadic cancer. *TP53* mutations, which are detected in only 5%–10% of AML cases, are associated with complex cytogenetic abnormalities and poor outcomes. AML with a complex karyotype accounts for 10%–15% of all adult AML cases. *TP53* somatic mutation was identified in about 60% of patients with AML patients who had a complex karyotype. According to this report, *TP53* mutation is strongly correlated with a complex karyotype.

AML associated with *TP53* mutation is associated with a poor response to chemotherapy and short overall survival. Moreover, it is highly associated with therapy-related AML. However, our patient did not have a previous history of malignancy. Treatment with *TP53* mutation has been challenging in patients with AML. Nevertheless, induction chemotherapy was more challenging because leukemia was complicated by severe infection including appendicitis. Wei et al. showed that CAG regimen was effective and safe for patients with AML, and it may be more effective than non-CAG regimens.

A new therapeutic strategy, including epigenetic drugs, has been found to be effective in targeting *TP53*-mutated AML. Venetoclax is a bcl-2 inhibitor, and azacitidine is a hypomethylating agent. Venetoclax combined with hypomethylating agents including azacitidine has a promising therapeutic effect. Apoptosis mediated by venetoclax may be independent of *TP53*. Combination therapy with these drugs has been recently approved for the treatment of AML by the National Health Insurance of Japan. Azacitidine-venetoclax therapy can be used as a maintenance therapy. In our case, the *TP53* c.566C>T mutation in AML cells was heterozygous. Nevertheless, no other *TP53* mutations were detected. If one allele of the *TP53* gene was a wild type and had a normal function, the prognosis of this patient might have been better than that of patients with homozygous or compound heterozygous mutation. However, we cannot rule out the risk of loss of function without mutation including epigenetic silencing. *TP53* mutations occur in 8% of de novo AML cases. In other solid malignancies, *TP53* mutation is found in more than half of the cases. *TP53* abnormalities without mutation occur more frequently than expected. Several mechanisms underlying *TP53* dysfunction have been reported. An algorithm for the *TP53*-based diagnostic workup and treatment of AML was developed. Hence, the mutated or nonmutated dysfunction of *TP53* must be identified for the treatment of AML.

Based on data in ClinVar, *TP53* c.566C>T mutation was considered a variant with uncertain significance. To the best of our knowledge, three cases with germline *TP53* c.566C>T mutation have been reported in detail. No case has met the classical criteria of Li-Fraumeni syndrome. Miyaki et al. reported a case of multiple colorectal cancer in a 73-year-old man, and examination results showed that tumor cells had a compound heterozygous mutation. Cho et al. presented a case of unilateral breast cancer in a 47-year-old woman, and assessment findings revealed that tumor cells had a homozygous mutation. The patient’s father and brother had esophageal and lung cancer, respectively. Her offspring underwent genetic
counseling and genetic testing. Choi et al.\(^3\) showed a case of fallopian tube cancer in a 56-year-old patient who had germline pathogenic mutation in the \(BRCA1\) gene. The patient’s sister had ovarian cancer. \(TP53\) mutation c.566C>T may be found incidentally. However, there is no association between this mutation and carcinogenesis. In our case, leukemia cells only exhibited heterozygous mutation. New somatic mutation did not occur in the \(TP53\) gene of leukemia cells. However, loss of function without mutation cannot be ruled out. Not only \(TP53\) mutation but also epigenetic deregulation of \(TP53\) expression is responsible for clinical heterogeneity.\(^9\) It was challenging to perform appropriate genetic counseling and surveillance on the patient and her family. Based on the family history, some members developed colorectal cancer at >50 years of age. In previously reported cases, colorectal cancer was diagnosed at the age of 73 years and breast cancer at the age of 47 years. This mutation may be correlated with relatively late-onset cancer. According to the family history of our patient and previous case reports, annual screening for breast and colorectal cancer may be recommended if a patient has germline \(TP53\) c.566C>T mutation. Momozawa et al.\(^4\) showed that \(TP53\) c.566C>T mutation was found in 19 of 7051 women with breast cancer. Moreover, they revealed that the mutation was found in 17 of 11,241 controls in a Japanese population. The odds ratio was 1.8 (0.9–3.7), and the \(p\) value was 0.088. Hence, the results between the two groups did not significantly differ. About 1 in 660 healthy women had the mutation, which may not be a pathogenic variant for Li-Fraumeni syndrome or Li-Fraumeni-like syndrome. The association between the mutation and breast cancer can possibly be weak. In AML or other malignancies, the effect of the mutation was unclear. In the current case, the patient was informed about the mutation. Hence, her offspring was recommended to undergo genetic counseling, and cancer screening must be discussed. Moreover, the patient and her family should be informed that future studies may change the current interpretation of the mutation.

Several companion diagnostic tests, which are used to assess a specific biomarker for qualifying a patient to receive a specific, associated therapy, have been applied in clinical settings. Most of them are somatic and/or germline genetic tests. In Japan, two gene panel tests for genomic profiling have recently been covered by the National Health Insurance. In other countries, the number of patients who undergo such gene panel tests is increasing. Hence, the number of germline mutation found incidentally will also increase. It is more challenging to interpret VUS found incidentally than pathogenic mutation. Therefore, patients with such incidental findings should undergo adequate genetic counseling.

**ACKNOWLEDGMENT**

None.

**CONFLICT OF INTEREST**

All authors declare that they have no conflict of interest.

**AUTHOR CONTRIBUTIONS**

HS, SM, and MH designed the research study. HS and YI performed the research. TH and HS analyzed the data. HS, YA, and MH wrote the manuscript. All authors contributed to editorial changes in the manuscript, read and approved the final manuscript.

**ETHICAL APPROVAL**

Ethics statement was published with written consent of the patient.

**CONSENT**

Written informed consent was obtained from the patient for publication of this case report and accompanying images.

**DATA AVAILABILITY STATEMENT**

The data that support the findings of this study are available from the corresponding author upon reasonable request.

**ORCID**

Hiroshi Sato https://orcid.org/0000-0002-0030-8078

**REFERENCES**

1. Miyaki M, Iijima T, Ohue M, et al. A novel case with germline \(p53\) gene mutation having concurrent multiple primary colon tumours. \textit{Gut}. 2003;52(2):304-306. doi:10.1136/gut.52.2.304
2. Cho Y, Kim J, Kim Y, Jeong J, Lee KA. A case of late-onset Li-Fraumeni-like syndrome with unilateral breast cancer. \textit{Ann Lab Med}. 2013;33(3):212-216. doi:10.3343/alm.2013.33.3.212
3. Choi MC, Bae JS, Jung SG, et al. Prevalence of germline \(BRCA\) mutations among women with carcinoma of the peritoneum or Fallopian tube. \textit{J Gynecol Oncol}. 2018;29(4):e43. doi:10.3802/jgo.2018.29.e43
4. Momozawa Y, Iwasaki Y, Parsons MT, et al. Germline pathogenic variants of 11 breast cancer genes in 7,051 Japanese patients and 11,241 controls. \textit{Nat Commun}. 2018;9(1):4083. doi:10.1038/s41467-018-06581-8
5. Rücker FG, Schlenk RF, Bullinger L, et al. TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome. \textit{Blood}. 2012;119(9):2114-2121. doi:10.1182/blood-2011-08-375758
6. Wei G, Ni W, Chiao JW, Cai Z, Huang H, Liu D. A meta-analysis of \(CAG\) (cytarabine, aclarubicin, G-CSF) regimen for the treatment of 1029 patients with acute myeloid leukemia and myelodysplastic syndrome. \textit{J Hematol Oncol}. 2011;14(4):46. doi:10.1186/1756-8722-4-46
7. Nechiporuk T, Kurtz SE, Nikolova O, et al. The TP53 apoptotic network is a primary mediator of resistance to BCL2 inhibition in AML cells. Cancer Discov. 2019;9(7):910-925. doi:10.1158/2159-8290.CD-19-0125

8. Prokocimer M, Molchadsky A, Rotter V. Dysfunctional diversity of p53 proteins in adult acute myeloid leukemia: projections on diagnostic workup and therapy. Blood. 2017;130(6):699-712. doi:10.1182/blood-2017-02-763086

9. Gargallo P, Yáñez Y, Segura V, et al. Li–Fraumeni syndrome heterogeneity. Clin Transl Oncol. 2020;22(7):978-988. doi:10.1007/s12094-019-02236-2

How to cite this article: Sato H, Matsuo S, Ando Y, Imamura Y, Hirose M. Germline TP53 c.566C>T mutation incidentally diagnosed during treatment for acute myeloid leukemia: A case report. Clin Case Rep. 2021;9:e05221. doi:10.1002/ccr3.5221